HIPRA, based in Spain, is a globally renowned pharmaceutical company, recognized for its commitment to the research, development and production of innovative vaccines since its founding in 1954.
Initially focused on the veterinary sector, HIPRA has led advances in biotechnology, designing preventive solutions that protect animal health and, in recent years, expanding its expertise to the human sector. The COVID-19 pandemic posed a global challenge that HIPRA decided to face by applying its vast knowledge in immunology and biotechnology. As a result, they developed Bimervax, a vaccine based on recombinant proteins that stands out for its ability to protect against SARS-CoV-2, including emerging variants.
Faced with the need to clearly explain the mechanism of action of this innovative vaccine, HIPRA was looking for a solution that combined scientific precision with a striking visual approach. Its goal was to reach both health professionals and the general public, ensuring understanding and confidence in this key tool against the pandemic.